NTRA

Natera, Inc.

Fundamental data last updated:November 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Diagnostics & Research

Exchange

NASDAQ

County of HQ

United States

Next Earnings Date

Pending Announcement

Business Summary

Natera's business model revolves around providing advanced genetic testing services. By leveraging proprietary technology, they deliver critical insights to healthcare providers, enhancing patient care. Their competitive moat lies in their innovative testing solutions and strong relationships with medical institutions. This integration into the healthcare ecosystem ensures a steady stream of revenue and customer loyalty.

 


Analyze NTRA on TradingView

VALUATION

P/E

-312.07

Market Cap ($M USD)

$61.18B

Forward P/E

45.24

PEG

7.93

PRICE TO SALES

22.60

PRICE TO BOOK

33.38

EV / EBITDA

-337.56

5-Year Average P/E

Free Cash Flow Yield

0.12%

DCF Value

$-318.87

Graham Number

N/A

Price to FCF

853.28

EV to FCF

841.38

Earnings Yield

-0.32%

FCF Yield

0.12%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.34

Next Year EPS Growth Estimate

-$1.45

Next Year Revenue Growth Estimate

$2.91B

Return on Equity (ROE)

-11.73%

FREE CASH FLOW

Operating Margin

-10.70%

Debt-to-Equity

0.13

Piotroski F-Score

3

Altman Z-Score

43.58

Return on Invested Capital (ROIC)

-10.02%

Current Ratio

3.00

Quick Ratio

2.85

Net Debt to EBITDA

4.77

Interest Coverage

-29.04

Gross Profit margin

65.30%

FCF PER SHARE

$0.50

REVENUE PER SHARE

$18.89

Analyze NTRA on TradingView

Gainseekers Quantitative Analysis

Summary

Natera, Inc. presents a perplexing valuation scenario. Despite a staggering market cap, the stock has traded significantly above its DCF value, suggesting a potential overvaluation. The Forward P/E of 45.24 hints at growth expectations, yet the negative Earnings Yield and ROIC raise red flags about profitability. However, the Altman Z-score of 43.58 indicates strong financial stability, a paradox given the negative earnings. This juxtaposition of high growth anticipation against weak earnings execution paints a complex picture for investors.

AI Exposure / Tech Reliance

Operating in the Medical Diagnostics & Research industry, Natera is well-positioned to leverage AI advancements. The sector's reliance on data and analytics aligns with AI's strengths, potentially enhancing diagnostic accuracy and operational efficiency. This adaptability could provide a competitive edge in a rapidly evolving technological landscape.

The Bull Case

For the bullish investor, Natera's story is one of potential and resilience. Despite a low Piotroski F-Score of 3, the company's robust Altman Z-score underscores its financial safety. The impressive gross profit margin of 65.30% suggests strong pricing power, while a manageable Debt/Equity ratio of 0.13 indicates prudent capital management. These factors, combined with a solid current ratio, make it an intriguing prospect for those betting on future growth.

The Bear Case

On the flip side, Natera's valuation metrics are daunting. With a Price/Book ratio of 33.38 and a Price/Sales of 22.60, the stock appears significantly overvalued. The negative EPS and poor FCF Yield further highlight cash flow struggles, while the stock's proximity to its 52-week high suggests technical overextension. These factors, coupled with a PEG Forward of 7.93, raise serious concerns about the stock's current pricing.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$386.00

Institutional Ownership %

1-Year Beta

1.50

Insider Buying % (6 Mo)

Distance to 52-Week High

3.06%

Distance to 52-Week Low

57.35%

EARNINGS SURPRISE %

4.85%

50-DAY SMA

$373.05

200-DAY SMA

$264.28

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.